Baigger Anja, Blasczyk Rainer, Figueiredo Constanca
Institute for Transfusion Medicine, Hanover Medical School, Hanover, Germany.
Transfus Med Hemother. 2017 Jun;44(3):165-173. doi: 10.1159/000477261. Epub 2017 May 23.
Platelet transfusions are used in standard clinical practice to prevent hemorrhage in patients suffering from thrombocytopenia or platelet dysfunctions. Recently, a constant rise on the demand of platelets for transfusion has been registered. This may be associated with several factors including demographic changes, population aging as well as incidence and prevalence of hematological diseases. In addition, platelet-regenerative properties have been started to be exploited in different areas such as tissue remodeling and anti-cancer therapies. These new applications are also expected to increase the future demand on platelets. Thus, in vitro generated platelets may constitute a highly desirable alternative to meet the rising demand on platelets. Several factors have been considered in the road trip of producing in vitro megakaryocytes and platelets for clinical application. From selection of the cell source, differentiation protocols and culture conditions to the design of optimal bioreactors, several strategies have been proposed to maximize production yields while preserving functionality. This review summarizes new advances in megakaryocyte and platelet differentiation and their production upscaling.
在标准临床实践中，血小板输注用于预防血小板减少症或血小板功能障碍患者的出血。最近，已记录到对输血用血小板的需求持续上升。这可能与多种因素有关，包括人口结构变化、人口老龄化以及血液疾病的发病率和患病率。此外，血小板再生特性已开始在组织重塑和抗癌治疗等不同领域得到应用。这些新应用预计也会增加未来对血小板的需求。因此，体外生成的血小板可能成为满足不断增长的血小板需求的理想替代方案。在将体外巨核细胞和血小板用于临床应用的过程中，已经考虑了几个因素。从细胞来源的选择、分化方案和培养条件到最佳生物反应器的设计，已经提出了几种策略来在保持功能的同时最大化产量。本综述总结了巨核细胞和血小板分化及其扩大生产方面的新进展。
